Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia

被引:1
|
作者
Yunivita, Vycke [1 ,2 ]
Gafar, Fajri [1 ,3 ,4 ]
Santoso, Prayudi [5 ,6 ]
Chaidir, Lidya [2 ,7 ]
Soeroto, Arto Y. [5 ,6 ]
Meirina, Triana N. [8 ]
Te Brake, Lindsey [9 ]
Menzies, Dick [3 ,4 ]
Aarnoutse, Rob E. [9 ]
Ruslami, Rovina [1 ,2 ,4 ]
机构
[1] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Pharmacol & Therapy, Bandung, Indonesia
[2] Univ Padjadjaran, Res Ctr Care & Control Infect Dis, TB Working Grp, Bandung, Indonesia
[3] Res Inst McGill Univ Hlth Ctr, Ctr Outcomes Res & Evaluat, Resp Epidemiol & Clin Res Unit, 5252 Blvd Maisonneuve Ouest,Off 3D 21, Montreal, PQ H4A 3S5, Canada
[4] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada
[5] Univ Padjadjaran, Fac Med, Dept Internal Med, Div Respirol & Crit Care, Bandung, Indonesia
[6] Hasan Sadikin Gen Hosp, Bandung, Indonesia
[7] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Microbiol, Bandung, Indonesia
[8] Univ Padjadjaran, Fac Med, Pharmacokinet Lab, Bandung, Indonesia
[9] Radboud Univ Nijmegen Med Ctr, Radboud Inst Med Innovat, Dept Pharm, Nijmegen, Netherlands
关键词
BACTERICIDAL ACTIVITY; CULTURE CONVERSION; TB PATIENTS; DRUGS; PHENOTYPE; GENOTYPE;
D O I
10.1093/jac/dkae057
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background :Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure-response relationships in RR/MDR-TB patients. Methods: We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18-65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10-15 mg/kg/day) for 9-11 months. Intensive pharmacokinetic sampling was performed after >= 2 weeks of treatment. Total plasma drug exposure (AUC(0-24)) and peak concentration (Cmax) were assessed using non-compartmental analyses. AUC(0-24)/MIC ratio of 85 and C-max/MIC ratio of 17.5 were used as exposure targets. Multivariable linear and logistic regression analyses were used to identify predictors of drug exposures and responses, respectively. Results :We consecutively enrolled 40 patients (median age 37.5 years). The geometric mean isoniazid AUC(0-24 )and Cmax were 35.4 h center dot mg/L and 8.5 mg/L, respectively. Lower AUC0-24 and Cmax values were associated (P < 0.05) with non-slow acetylator phenotype, and lower Cmax values were associated with male sex. Of the 26 patients with MIC data, less than 25% achieved the proposed targets for isoniazid AUC(0-24)/MIC (n = 6/26) and C-max/MIC (n = 5/26). Lower isoniazid AUC0-24 values were associated with delayed sputum culture conversion (>2 months of treatment) [adjusted OR 0.18 (95% CI 0.04-0.89)]. Conclusions :Isoniazid exposures below targets were observed in most patients, and certain risk groups for low isoniazid exposures may require dose adjustment. The effect of low isoniazid exposures on delayed culture conversion deserves attention.
引用
收藏
页码:977 / 986
页数:10
相关论文
共 50 条
  • [31] TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS
    COHN, DL
    JOURNAL OF HOSPITAL INFECTION, 1995, 30 : 322 - 328
  • [32] Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis
    van Rijn, Sander P.
    van Altena, Richard
    Akkerman, Onno W.
    van Soolingen, Dick
    van der Laan, Tridia
    de Lange, Wiel C. M.
    Kosterink, Jos G. W.
    van der Werf, Tjip S.
    Alffenaar, Jan-Willem C.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 47 (04) : 1229 - 1234
  • [33] Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis
    Lee, H. W.
    Kim, D. W.
    Park, J. H.
    Kim, S. -D.
    Lim, M. -S.
    Phapale, P. B.
    Kim, E. -H.
    Park, S. K.
    Yoon, Y. -R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2009, 13 (09) : 1161 - 1166
  • [34] Evaluation of High-Dose Isoniazid in MultidrugResistant Tuberculosis Treatment
    Gerussi, Valentina
    Petersen, Tania
    Bonnet, Isabelle
    Aubry, Alexandra
    Bachir, Marwa
    Gyde, Esther
    Morel, Florence
    Poignon, Corentin
    Rached, Brigitte
    Pourcher, Valerie
    Rioux, Christophe
    Vallois, Dorothee
    Veziris, Nicolas
    Robert, Jerome
    Guglielmetti, Lorenzo
    EMERGING INFECTIOUS DISEASES, 2025, 31 (03) : 633 - 635
  • [35] Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation
    Afanas'ev, Maxim V.
    Ikryannikova, Larisa N.
    Il'ina, Elena N.
    Sidorenko, Sergey V.
    Kuz'min, Aleksey V.
    Larionova, Elena E.
    Smirnova, Tat'yana G.
    Chernousova, Larisa N.
    Kamaev, Eugeny Yu
    Skorniakov, Sergey N.
    Kinsht, Vladimir N.
    Cherednichenko, Andrey G.
    Govorun, Vadim M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (06) : 1057 - 1064
  • [36] Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation
    Lim, Sazlyna Mohd Sazlly
    Sime, Fekade Bruck
    Roberts, Jason A.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (06) : 726 - 745
  • [37] Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients
    Yun, Hwi-yeol
    Chang, Min Jung
    Jung, Heeyoon
    Chang, Vincent
    Wang, Qianwen
    Strydom, Natasha
    Yoon, Young-Ran
    Savic, Radojka M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [38] Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis
    Mvelase, Nomonde Ritta
    Balakrishna, Yusentha
    Lutchminarain, Keeren
    Mlisana, Koleka
    BMJ OPEN, 2019, 9 (11):
  • [39] Pharmacokinetics of Ofloxacin and Levofloxacin for Prevention and Treatment of Multidrug-Resistant Tuberculosis in Children
    Thee, S.
    Garcia-Prats, A. J.
    McIlleron, H. M.
    Wiesner, L.
    Castel, S.
    Norman, J.
    Draper, H. R.
    van der Merwe, P. L.
    Hesseling, A. C.
    Schaaf, H. S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) : 2948 - 2951
  • [40] Capacity of Abbott RealTime MTB RIF/INH to detect rifampicin- and isoniazid-resistant tuberculosis
    Hofmann-Thiel, S.
    Molodtsov, N.
    Duffner, C.
    Kadyrov, A.
    Kalmambetova, G.
    Kabirov, O.
    Rajabov, A.
    Parpieva, N.
    Sayfutdinov, Z.
    Vogel, M.
    Vogel, H.
    Antonenka, U.
    Hoffmann, H.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2019, 23 (04) : 458 - 464